Cibus (CBUS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Voting matters and shareholder proposals
Election of nine directors to serve until the next annual meeting and until successors are elected and qualified.
Advisory vote to approve the compensation of Named Executive Officers.
Ratification of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Other business may be addressed as properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Nine nominees are presented for election to the board, including Mark Finn, Peter Beetham, Kimberly A. Box, Jean-Pierre Lehmann, August Moretti, Gerhard Prante, Rory Riggs, Thomas Urban, and Craig Wichner.
Executive compensation and say-on-pay
Advisory vote is being held to approve the compensation of Named Executive Officers.
Latest events from Cibus
- Annual meeting covers director elections, executive pay, auditor ratification, and governance policies.CBUS
Proxy filing20 Apr 2026 - Advanced Rice and ingredient programs, cut costs, and raised funds for 2026 milestones.CBUS
Q4 202517 Mar 2026 - Gene-edited crop traits target global markets, with royalties expected from 2026 onward.CBUS
17th Annual LD Micro Main Event Conference3 Feb 2026 - Q2 2024 saw commercial expansion, advanced trait milestones, and a $28.5M net loss.CBUS
Q2 20242 Feb 2026 - Gene editing is transforming agriculture, driving efficiency, sustainability, and high-margin growth.CBUS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Gene editing traits for major crops are poised for rapid global adoption and strong royalty growth.CBUS
Sidoti Micro-Cap Virtual Conference2 Feb 2026 - Q3 net loss of $201.5M from goodwill impairment; cost savings and commercialization ongoing.CBUS
Q3 202415 Jan 2026 - Industrialized gene editing and royalty-driven traits set the stage for scalable agtech growth.CBUS
Sidoti Micro-Cap Virtual Conference9 Jan 2026 - Q4 2024 net loss narrowed, cash runway extended, and gene editing platforms advanced.CBUS
Q4 202424 Dec 2025